Leonardo Farol

Leonardo Farol, M.D.

  • Staff Physician, Department, Hematology & Hematopoietic Cell Transplantation

Leonardo Farol, M.D.

Clinical Specialties
  • Hematology/Oncology
Areas of Expertise
  • Bone marrow transplantation
Leonardo Farol, M.D., is a board-certified hematologist who specializes in bone marrow transplants. He is also a member of the City of Hope/Kaiser Bone Marrow Transplantation Team.

Farol attended medical school at the University of Irvine before completing his internship and residency in Evanston, Illinois. He completed a fellowship in hematology and oncology at New York University, and another one in Bone Marrow Transplantation at City of Hope.

Farol grew up in Southern California and is glad to be back and closer to friends and family following his sojourns to the Midwest and East Coast. He says the practicing medicine as a career is a special opportunity to connect and help people in a meaningful way, listening and responding to patients with specialized skills and knowledge. Communication is an important part of his practice, he says, and he’s honored that patients have entrusted him with their care. He strives to treat them as he would his own family.

When not in the office, Farol keeps himself fit with daily CrossFit classes. He believes that physical and mental health are important to a physician, and CrossFit allows him to relieve stress and get his blood pumping at the same time.  
 
  • 2008-Present, Staff Physician, Kaiser Permanente/City of Hope, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
  • 2006-2008, Kaiser Permanente Fontana, Dept of Hematology/Oncology

Locations

Duarte

1500 East Duarte Road, Duarte, CA, 91010

Get Directions

Phone :  626-256-4673

Degrees

  • 1998, M.D., University of California, Irvine, CA
  • 1994, B.A., Biochemistry, Occidental College, Los Angeles, CA

Fellowship

  • 2005-2006, Bone Marrow Transplant Fellowship, City of Hope, Duarte, CA
  • 2002-2005, Hematology/Oncology, New York University, New York, NY

Residency

  • 1998-2001, Internal Medicine, Northwestern University (Evanston Northwestern Healthcare), Evanston, IL
  • 2002, American Board of Internal Medicine
  • 2005, Medical Oncology
  • 2005, Hematology
  • Farol L, Hymes K: Bexarotene: A Clinical Review. Expert Rev Anticancer Therapy (2004) 4(2): 180- 8. PMID: 15056048
  • Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ. Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant. 2012 Mar;l8(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22. PMID: 22198542
  • Chen R, Palmer JM, Thomas SH, Tsai NC, Farol L, Nademanee A, Forman SJ, Gopal AK. Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2012 Jun 28;119(26):6379-81. DOI:10.1182/blood-2012-03-418673. Epub 2012 May 18. PMID: 22611160
  • Krishnan AY, Wang S, Palmer JM, Tsai NC, Thomas SH, Htut M, Farol L, Forman SJ. A phase I study of intravenous plerixafor following cyclophosphamide mobilization in patients with multiple myeloma. Leuk Lymphoma. 2014 Jan;55(1):201-3. DOI: 10.3109/10428194.2013.794268. No abstract available. PMID:23573824
  • Chen R, Palmer JM, Tsai NC, Thomas SH, Siddiqi T, Popplewell L, Farol L, Nademanee A, Forman SJ. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation/or Hodgkin lymphoma. Biol Blood Marrow Transplant. 2014 Nov;20(11):1864-8. DOI: 10.1016/j.bbmt.2014.06.037. PMID:25008328
  • Armenian SH, Xu L, Ky B, Sun C, Farol LT, Pal SK, Douglas PS, Bhatia S, Chao C. Cardiovascular Disease Among Survivors of Adult-Onset Cancer: A Community-Based Retrospective Cohort Study. J Clin Oncol. 2016 Apr 1;34(10):1122-30. DOI: 10.1200/JCO.2015.64.0409. PMID:26834065
  • Nakamura R, La Rosa C, Longmate J, Drake J, Slape C, Zhou Q, Lampa MG, O'Donnell M, Cai JL, Farol L, Salhotra A, Snyder DS, Aldoss I, Forman SJ, Miller JS, Zaia JA, Diamond DJ. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF035 l 2676 (CMVPep Vax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1 b trial. Lancet Haematol. 2016 Feb;3(2):e87-98. DOI: 10.1016/S2352-3026(15)00246-X. PMID:26853648
  • Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J. Phase I Trial of Total Marrow and Lymphoid Irradiation Transplant Conditioning in Patients with Relapsed/Refractory Acute Leukemia. Biol Blood Marrow Transplant. 2017 Jan 10. pii: S1083- 8791(17)30192-l. DOI: 10.1016/j.bbmt.2017.01.067. [Epub ahead of print]
Back To Top